Volume 4, Issue 7
Editorialp. 587–590
Clinical trial transparency and the evaluation of new medicines
Author(s): Bina Rawal and Bryan R Deane
Editorialp. 591–594
Macrolides for bronchiectasis and chronic obstructive pulmonary disease: should we worry about antimicrobial resistance?
Author(s): David J Serisier
News and Viewsp. 595–599
News: Amendment to UK Patent Act provides further exception to patent infringement
Commentaryp. 601–604
Cancer cachexia: an unmet need in cancer treatment
Author(s): Ozkan Kanat, Bert H O ™Neil
Clinical Trail Methodologyp. 605–618
Outcome measures in amyotrophic lateral sclerosis clinical trials
Author(s): Sabrina Paganoni, Merit Cudkowicz, James D Berry
Clinical Trail Outcomesp. 619–639
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Author(s): Rupert Bauersachs
Clinical Trail Outcomesp. 641–648
Oral iron therapies in development for iron deficiency in chronic kidney disease
Author(s): David William Mudge & David Wayne Johnson
Clinical Trail Outcomesp. 649–671
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Author(s): Edward L Nelson
